It has recently been reported that a longer interval to esophagectomy following induction therapy results in higher pathologic response rates. The current study used data from the CROSS trial to determine whether a longer interval to esophagectomy following induction therapy results in improved survival. Time to surgery (TTS) was a median of 48 day
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Thoracic
October 8, 2014
The Comprehensive Complication Index (CCI) was compared to more standard methods of categorizing complications for their utility in assessing outcomes after randomized surgical trials. The CCI outperformed standard methods in 2 of 3 published randomized trials (pancreatic and esophageal surgery), demonstrating significant differences in outcomes whe
October 6, 2014
A right upper lobe sleeve lobectomy, uniportally.
October 6, 2014
This video demonstrates the surgical technique of videothoracoscopic left internal artery lymphadenctomy for lymph nodal recurrence of breast cancer already submitted to standard chemoradiotherapy.
October 1, 2014
Massimo Caputo of Rush University Medical Center in Chicago discusses his experience as a CTSNet contributor. Dr. Caputo has contributed four videos on congenital heart surgery to CTSNet’s educational resources.
October 1, 2014
Using a single institution database, the authors propensity score matched patients receiving wedge resection, wedge resection plus brachytherapy, or SBRT for early stage NSCLC. Survival was assessed at a median of 35 mos. Overall recurrence was higher for SBRT vs wedge (30% vs 9%), and recurrence-free and disease-free survival were better after wed
September 25, 2014
This video demonstrates a VATS lobectomy on a 54-year-old female patient with localized bronchiectasis.
September 25, 2014
Costs of lung cancer screening were determined for individuals with a 2% or greater risk of lung cancer over 3 years for 2059 subjects participating in the Pan-Canadian Early Detection of Lung Cancer Study. During the first 18 mos of screening the per-person cost was $453. Surgical therapy cost $33,344 over 2 years compared to costs of treating adv
September 25, 2014
This phase II trial evaluated outcomes of isolated lung perfusion with Melphalan and complete surgical resection for pulmonary metastases from colorectal cancer or sarcoma in 50 pts. Surgical mortality was 0%, but morbidity (primarily grade 3 or 4 pulmonary morbidity) was 44%. 30 patients suffered local recurrence. 3-year survival was 57% and recu
September 25, 2014
A model for predicting lung cancer in patients with suspicious lung nodules (TREAT) was developed using single institutional data (Vanderbilt), validated using data from another institution, and compared to the Mayo Clinic predictive model. The model accuracy was 87% in the development cohort and 89% in the validation cohort, compared to 80% in the